Kevin M. Slawin, Chief Technology Officer at BELLICUM PHARMACEUTICALS, INC (BLCM), sold 2,719 shares at $13.99 ($38K) on 2016-07-18, disclosed to the SEC on 2016-07-19.
Scheduled sale ($38k) by Chief Technology Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| BLCM | SELL | 2016-09-23 | $936K | — | Filing → |
| BLCM | SELL | 2016-09-20 | $92K | — | Filing → |
| BLCM | SELL | 2016-08-17 | $2.0M | — | Filing → |